The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a CD209-binding compound or antibody in an amount and for a time sufficient to suppress neutrophil movement into the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. The disclosure further relates to compositions usable with these methods and method of detecting CD209-binding compounds and antibodies able to affect neutrophil movement or adhesion.
